This allows you to use pre-tax dollars for GLP-1 medications and program fees
Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027
It includes access to Noom's digital longevity companion for behavioral support, at-home health testing to monitor 17 biomarkers for long-term health and personalized GLP-1 microdosing for those who qualify
Dulaglutide (Brand name: Trulicity) Administered as a weekly injection, primarily for diabetes
This phase represents the medication's full therapeutic effect combined with your body's metabolic adjustments
A similar study published last year in Diabetes, Obesity and Metabolism found that switching from a weekly GLP-1 dose to a dose every other week helped people maintain about 75 percent of their weight loss
